Doan T, Grammer L C, Yarnold P R, Greenberger P A, Patterson R
Department of Medicine, Northwestern Memorial Hospital, Chicago, Illinois, USA.
Ann Allergy Asthma Immunol. 1996 Jun;76(6):513-8. doi: 10.1016/S1081-1206(10)63270-X.
Asthma is the single disease that accounts for the largest proportion of total health care cost in the US.
To analyze whether an asthma management program affected the cost of subsequent asthma care for patients in whom intubation had been necessary.
We evaluated patients with asthma who (1) had required intubation for treatment of status asthmaticus; (2) were 45 years old or younger; (3) had regular follow-up visits in our clinic for 1 year after initial evaluation; and (4) had complete medical records 1 year before and 1 year after the intervention for our evaluation. Medical costs of asthma treatment for each patient were determined for 1 year before and 1 year after intervention. The program included patient education, regular outpatient visits, specialist care, and access to the Allergy Immunology emergency call service. The outcome measures were the total cost of care, inpatient hospitalizations, outpatient services, emergency services, and medicine costs.
Nine patients [mean age 19.6 years (SD = 9.9)] fulfilled the criteria (six women and three men). The mean duration of asthma was 14.0 years (SD = 9.7). The mean total cost of care decreased from $43,066 to $4,914 (t = -4.53, P < .001) and inpatient hospitalization costs decreased from $40,253 to $1,926 (t = -4.50, P <.001). There was, however, no significant difference in the mean pre-intervention versus post-intervention cost of emergency services, outpatient services, or medicine costs.
The intervention--which included education, specialist care, regular outpatient visits, and access to an emergency call service--significantly reduced the cost of asthma care in our population of patients intubated for asthma.
在美国,哮喘是占总医疗费用比例最大的单一疾病。
分析哮喘管理项目是否会影响曾需要插管治疗的患者后续哮喘治疗的费用。
我们评估了符合以下条件的哮喘患者:(1)因哮喘持续状态需要插管治疗;(2)年龄在45岁及以下;(3)在初始评估后在我们诊所进行了1年的定期随访;(4)在干预前1年和干预后1年有完整的病历供我们评估。确定每位患者干预前1年和干预后1年的哮喘治疗医疗费用。该项目包括患者教育、定期门诊就诊、专科护理以及使用过敏免疫急救电话服务。结果指标为护理总费用、住院费用、门诊服务费用、急诊服务费用和药品费用。
9名患者[平均年龄19.6岁(标准差=9.9)]符合标准(6名女性和3名男性)。哮喘平均病程为14.0年(标准差=9.7)。护理总费用均值从43,066美元降至4,914美元(t=-4.53,P<.001),住院费用从40,253美元降至1,926美元(t=-4.50,P<.001)。然而,干预前与干预后急诊服务、门诊服务或药品费用的均值无显著差异。
该干预措施——包括教育、专科护理、定期门诊就诊以及使用急救电话服务——显著降低了我们研究中因哮喘插管患者的哮喘护理费用。